The multiple sclerosis therapeutic agents are intended to promote neurorepair and neuroprotection to prevent disease progression. The disease modifying therapeutics are currently under clinical development to specifically target the disease while avoiding frequent therapeutic administrations. A variety of corticosteroids, immunosuppressants and monoclonal antibodies are approved and recommended to reduce inflammation in multiple sclerosis. The complex nature of disease with its unique individual patient course renders variable clinical outcomes in different patients. Although there is no cure for multiple sclerosis, the currently available therapeutics modify the disease course, accelerate recovery from attacks, and help in managing symptoms.
Market Dynamics
The major factors driving growth of the multiple sclerosis therapeutics market include rise in research and development ultimately leading to the launch of novel drug candidates and the rising prevalence of the condition in children. For instance, in 2014, Plegridy (peginterferon beta-1a) manufactured by Biogen, a disease modifying therapy was approved for the long-term treatment of relapsing forms of multiple sclerosis. According to Multiple Sclerosis Society, approximately five to ten per cent of people with MS experienced their first symptoms before the age of 16. However, the inability of drugs to prevent disease progression and disability, side effects of the approved drugs such as increased risk of infections, flu-like symptoms and progressive multifocal leukoencephalopathy (PML), a viral disease of the brain are the factors hindering market growth.
Key features of the study:
- This report provides in-depth analysis of multiple sclerosis therapeutics market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global multiple sclerosis therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
- Key companies covered as a part of this study include Novartis AG, Teva Pharmaceuticals Industries Ltd., Sanofi Genzyme, Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., and AbbVie, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, market expansion, and marketing tactics
- The global multiple sclerosis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the multiple sclerosis therapeutics market
Detailed Segmentation:
- Global Multiple Sclerosis Therapeutics Market, By Drug Class:
- Beta Interferon
- Corticosteroids
- Monoclonal Antibodies
- Antineoplastic Agents
- Others
- Global Multiple Sclerosis Therapeutics Market, By Route of Administration:
- Global Multiple Sclerosis Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
- Global Multiple Sclerosis Therapeutics Market, By Geography:
- North America
- By Drug Class:
- Beta Interferon
- Corticosteroids
- Monoclonal Antibodies
- Antineoplastic Agents
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
- By Country:
- Latin America
- By Drug Class:
- Beta Interferon
- Corticosteroids
- Monoclonal Antibodies
- Antineoplastic Agents
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Class:
- Beta Interferon
- Corticosteroids
- Monoclonal Antibodies
- Antineoplastic Agents
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Class:
- Beta Interferon
- Corticosteroids
- Monoclonal Antibodies
- Antineoplastic Agents
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Class:
- Beta Interferon
- Corticosteroids
- Monoclonal Antibodies
- Antineoplastic Agents
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Class:
- Beta Interferon
- Corticosteroids
- Monoclonal Antibodies
- Antineoplastic Agents
- Others
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
- By Country:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Novartis AG*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Bayer AG
- Pfizer, Inc.
- Biogen Idec
- Merck & Co., Inc.
- AbbVie, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Content - Multiple Sclerosis Therapeutics Market
